Trial Profile
Pneumococcal vaccine response in COPD [chronic obstructive pulmonary disease]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms PNEUMO
- 19 Mar 2024 Results published in the Merck & Co Media Release
- 19 Mar 2024 According to a Merck & Co media release, data from this study presented at the 13th Meeting of the International Society of Pneumonia and Pneumococcal Diseases (ISPPD) in Cape Town, South Africa.
- 26 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.